TSCAN THERAPEUTICS, INC. Investing Cash Flow
TSCAN THERAPEUTICS, INC. (TCRX) reported Investing Cash Flow of -$535.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$465.00K, a 100.96% decline year-over-year.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$70.00K, a 100.52% decline year-over-year.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $14.83M, a 45.67% decline year-over-year.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $32.58M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was $109.37M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$52.61M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$60.76M.
- TSCAN THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$4.22M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$465.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$535.00K 10-Q · filed 2026-08-12 | $14.29M derived: sum of 3 quarters · filed 2026-08-12 | $46.87M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$70.00K 10-Q · filed 2026-05-06 | $14.76M derived: sum of 2 quarters · filed 2026-05-06 | $47.34M derived: sum of 3 quarters · filed 2026-05-06 | $95.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $14.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $47.41M derived: sum of 2 quarters · filed 2026-03-04 | $95.84M derived: sum of 3 quarters · filed 2026-08-12 | $109.37M 10-K · filed 2026-03-04 |
| 2025-09-30 | $32.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $81.01M derived: sum of 2 quarters · filed 2026-08-12 | $94.54M 10-Q · filed 2025-11-12 | $121.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $48.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $61.97M 10-Q · filed 2026-08-12 | $89.26M derived: sum of 3 quarters · filed 2026-08-12 | $6.91M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $13.53M 10-Q · filed 2026-05-06 | $40.82M derived: sum of 2 quarters · filed 2026-05-06 | -$41.53M derived: sum of 3 quarters · filed 2026-05-06 | -$75.25M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $27.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$55.06M derived: sum of 2 quarters · filed 2026-03-04 | -$88.78M derived: sum of 3 quarters · filed 2026-03-04 | -$52.61M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$82.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$116.07M derived: sum of 2 quarters · filed 2025-11-12 | -$79.91M 10-Q · filed 2025-11-12 | -$77.99M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$33.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.45M 10-Q · filed 2025-08-12 | $4.36M derived: sum of 3 quarters · filed 2025-08-12 | -$57.05M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $36.16M 10-Q · filed 2025-05-06 | $38.08M derived: sum of 2 quarters · filed 2025-05-06 | -$23.34M derived: sum of 3 quarters · filed 2025-05-06 | -$23.76M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$59.50M derived: sum of 2 quarters · filed 2025-03-05 | -$59.92M derived: sum of 3 quarters · filed 2025-03-05 | -$60.76M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$61.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$61.83M derived: sum of 2 quarters · filed 2024-11-12 | -$62.67M 10-Q · filed 2024-11-12 | -$64.05M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$420.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$1.26M 10-Q · filed 2024-08-12 | -$2.63M derived: sum of 3 quarters · filed 2024-08-12 | -$3.06M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$838.00K 10-Q · filed 2024-05-13 | -$2.21M derived: sum of 2 quarters · filed 2024-05-13 | -$2.64M derived: sum of 3 quarters · filed 2024-05-13 | -$4.53M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$1.80M derived: sum of 2 quarters · filed 2024-03-06 | -$3.69M derived: sum of 3 quarters · filed 2024-03-06 | -$4.22M 10-K · filed 2024-03-06 |
| 2022-09-30 | -$424.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.32M derived: sum of 2 quarters · filed 2023-11-09 | -$2.85M 10-Q · filed 2023-11-09 | -$5.06M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$2.42M 10-Q · filed 2023-08-10 | -$4.63M derived: sum of 3 quarters · filed 2023-08-10 | -$5.49M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$531.00K 10-Q · filed 2023-05-10 | -$2.74M derived: sum of 2 quarters · filed 2023-05-10 | -$3.60M derived: sum of 3 quarters · filed 2023-05-10 | -$7.51M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$3.06M derived: sum of 2 quarters · filed 2023-03-08 | -$6.98M derived: sum of 3 quarters · filed 2023-03-08 | -$9.94M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$853.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$4.77M derived: sum of 2 quarters · filed 2022-11-09 | -$7.73M 10-Q · filed 2022-11-09 | -$9.12M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$6.88M 10-Q · filed 2022-08-10 | -$8.26M derived: sum of 3 quarters · filed 2022-08-10 | -$9.61M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$2.96M 10-Q · filed 2022-05-12 | -$4.34M derived: sum of 2 quarters · filed 2022-05-12 | -$5.69M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$2.73M derived: sum of 2 quarters · filed 2022-03-09 | -$4.24M 10-K · filed 2022-03-09 | |
| 2020-09-30 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$2.85M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$1.51M 10-Q · filed 2021-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |